Stone X Group Inc. Genprex, Inc. Transaction History

Stone X Group Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 13, 2025	BUY	$0.19 - $0.37 $6,679 - $13,007	35,156 New	35,156 $8.09 Million
Q3 2023 Aug 13, 2025	BUY	$0.37 - $1.04 $13,005 - $36,556	35,150 New	35,150 $13.9 Million
Q2 2023 Aug 13, 2025	SELL	$0.74 - $1.1 $1,721 - $2,558	-2,326 Reduced 6.21%	35,150 $33.3 Million
Q1 2023 Aug 13, 2025	BUY	$0.76 - $1.78 $1,767 - $4,140	2,326 Added 6.62%	37,476 $34.1 Million
Q4 2022 Aug 13, 2025	BUY	$1.0 - $58.8 $35,150 - $2.07 Million	35,150 New	35,150 $51 Million
Q1 2022 Aug 13, 2025	BUY	$1.82 - $3.5 $63,973 - $123,025	35,150 New	35,150 $79.4 Million
Q1 2022 Aug 13, 2025	BUY	$1.82 - $3.5 $63,973 - $123,025	35,150 New	35,150 $79.4 Million
Q4 2021 Aug 13, 2025	BUY	$1.21 - $2.7 $42,531 - $94,905	35,150 New	35,150 $46,000
Q2 2019 Jul 17, 2019	BUY	$1.2 - $1.85 $42,180 - $65,027	35,150 New	35,150 $44,000
Q2 2019 Jul 12, 2019	SELL	$1.2 - $1.85 $42,180 - $65,027	-35,150 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$1.0 - $2.15 $35,150 - $75,572	35,150 New	35,150 $38,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $280M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

Stay updated on Stone X Group Inc. with notifications on news.